After surprise rejection of hemophilia gene therapy, BioMarin asks FDA to approve dwarfism drug
August 20, 2020 at 17:59 PM EDT
BioMarin's drug targets children with achondroplasia, the most common form of dwarfism.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|